Restoring Manufacturing Readiness Following a Major Facility Change

Facility transformation and equipment relocation reshaped the manufacturing environment.

The manufacturing cleanroom and facilities underwent significant upgrades, and the Manufacturing and QC operations were relocated. Restoring manufacturing capability required understanding how those changes affected equipment qualification and the validated state of core manufacturing processes for the primary product.

As the program lead, I coordinated equipment requalification and revalidation of the primary product’s core manufacturing processes, alongside continued manufacturing and clinical-supply considerations.

Readiness was more than a list of completed activities.

The challenge was coordinating interdependent technical activities in the right sequence. Engineering, Manufacturing, Quality, and QC each held part of the answer. I connected all of those departments and aligned them with shared resources, requirements, dependencies, schedule constraints, and clinical supply timelines.

Completing an individual qualification activity did not necessarily make the process ready. The program needed a shared view of what each completed activity enabled—and what still prevented manufacturing from proceeding.

My role: technical direction and cross-functional execution.

I led the cross-functional program, helping establish priorities, technical direction, sequencing, impact assessments, and execution plans. I connected work across multiple departments, monitored their progress and dependencies, facilitated resolution of issues and changes, and regularly communicated status and risk to senior site leadership. Alongside program leadership, I remained engaged in the requalification work, authoring and executing protocols for multiple systems and reviewing or supporting qualification activities for the Engineering team. My scope included visual inspection and packaging equipment, controlled-storage systems, moisture analysis, the ViewPoint environmental monitoring system, and computer systems supporting release testing of tablets.

My leadership contribution was to structure the program, coordinate expertise across functions, and support the decisions required to move the program toward readiness.

Structure the problem before structuring the schedule.

When I took the initiative to lead this program, individual departments were making progress, but there was no unifying framework connecting deliverables, dependencies, decisions, and overall readiness across functions. Before establishing a schedule, I structured the work so the team could see how the work across departments was interconnected and what GMP readiness required.

Make dependencies visible. Keep parallel work moving.

Facility and utility readiness enabled equipment requalification, which then enabled manufacturing preparation and process revalidation. Quality review was integrated throughout and supported multiple stages rather than serving as a final checkpoint.

The dependency path is simplified. Actual program planning had to account for overlapping activities and functional resources shared across workstreams. A delay in one area could constrain another even when its own task list was progressing.

Key Decisions & Tradeoffs

The categories below describe the decision framework that we implemented for this complex manufacturing program. They are not accounts of specific deviations, controversial decisions, or changes to GMP requirements.

Focus on the risks that could prevent readiness.

The objective was not to eliminate all uncertainty. It was to identify which risks could prevent or delay manufacturing readiness, understand their operational consequences, and focus leadership attention accordingly.

Equipment status, validation completion, QC readiness, and resources were interdependent. Schedule risks mattered because delays could affect manufacturing capability and continued clinical supply.

Execution required a cadence—not a static plan.

Throughout a 12-month program, technical findings, resource constraints, scope creep, and execution outcomes inevitably altered the plan. I kept the program flexible while maintaining focus on the success criteria for manufacturing readiness.

The loop returned to planning whenever assumptions changed. I regularly communicated with stakeholders to keep them aligned on progress, issues, required decisions, and the manufacturing consequences of changes or delays.

Manufacturing capability restored.

With the closure of my change control to return the site to GMP production, all required equipment and core manufacturing processes were back online and ready for GMP use following the major facility upgrade and relocation of all equipment within the cleanroom.

Lessons I carry forward.